1. Home
  2. GLUE vs TBLA Comparison

GLUE vs TBLA Comparison

Compare GLUE & TBLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Monte Rosa Therapeutics Inc.

GLUE

Monte Rosa Therapeutics Inc.

HOLD

Current Price

$16.03

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Logo Taboola.com Ltd.

TBLA

Taboola.com Ltd.

HOLD

Current Price

$3.09

Market Cap

1.1B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
GLUE
TBLA
Founded
2019
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Programming Data Processing
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.1B
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
GLUE
TBLA
Price
$16.03
$3.09
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
4
Target Price
$29.50
$5.00
AVG Volume (30 Days)
776.4K
2.0M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$75,622,000.00
N/A
Revenue This Year
$84.02
$7.95
Revenue Next Year
N/A
$5.62
P/E Ratio
$72.42
$42.36
Revenue Growth
N/A
N/A
52 Week Low
$3.50
$2.63
52 Week High
$25.77
$4.65

Technical Indicators

Market Signals
Indicator
GLUE
TBLA
Relative Strength Index (RSI) 33.37 39.28
Support Level $14.51 $3.03
Resistance Level $16.66 $3.56
Average True Range (ATR) 1.02 0.17
MACD -0.19 0.03
Stochastic Oscillator 7.06 40.94

Price Performance

Historical Comparison
GLUE
TBLA

About GLUE Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

About TBLA Taboola.com Ltd.

Taboola is a performance-based native advertising network designed to improve click-through rates and increase monetizable events for advertisers while generating yield for publisher websites. Taboola competes with Google, Amazon, and other advertising networks that display stories and products on websites. The company was founded in 2007 in Israel. It acquired Connexity, a retail advertising network, in 2021, and entered a partnership with Yahoo in 2022, in which it acquired exclusive native advertising rights over Yahoo digital properties in exchange for a 25% equity stake in the company.

Share on Social Networks: